News FDA's Duchenne drug approval greeted with joy, but remains c... FDA will require efficacy evidence.
Views & Analysis Regulatory timelines in the Asia-Pacific Snapshot of clinical trial application processes in the region.
Views & Analysis Are European incentives speeding access in rare cancer treat... Examining the impact of support programmes for orphan treatments.
News UK could quit EU drug regulation system - minister Nothing has been ruled in or out, says George Freeman.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
